Adherence to diabetes medication has been linked improved glycemic levels and lower costs, but previous research on adherence typically involved oral antidiabetic or insulin. This study examines how persistence once-daily liraglutide impact control economic outcomes in a real-world population of adult type 2 (T2D) patients. A retrospective cohort using administrative claims data from July 2009 through September 2013. Patients aged ≥18 years with T2D treated were identified (index date =...

To describe 24-month treatment patterns, healthcare resource utilization (HCRU), and direct costs of patients initiating galcanezumab (GMB) versus standard care migraine preventive medications (SOC), stratified by gender type. This retrospective cohort study used Optum's® de-identified Market Clarity database (September 2018-March 2020) included adults with ≥1 claim for GMB or SOC. Patients in the were (female/male) type (CM/EM), propensity score matched 1:1 to SOC cohort. Treatment...

Given the lack of real-world data on oral semaglutide use outside clinical trials, purpose this study was to describe dose, prescriber specialty, and change in hemoglobin A1c (HbA1c) after 6 months treatment for patients with type 2 diabetes mellitus (T2DM).This a retrospective among adult T2DM ≥ 1 claim between November 1, 2019`1-June 30, 2020. Patients had continuous health plan enrollment 12 prior (pre-index) following (post-index) date first (index). Dose at initiation specialty...

Objective: Prostate cancer is a leading cause of death in men the US. Castration-resistant prostate (CRPC) an advanced form disease and has poor prognosis limited treatment options. The objective this study was to identify patients with CRPC from medical claims database, determine cancer-related economic burden healthcare utilization these patients.Methods: This retrospective using enrollment information large US database linkable laboratory data. Male aged 40 or older who were diagnosed...

Objective:To explore treatment patterns and resource utilization cost for subjects with pulmonary arterial hypertension (PAH).Research design:Retrospective claims database analysis of 706 patients PAH enrolled in a large, geographically diverse US managed-care organization.Results:In the final sample treated bosentan (n = 251) or sildenafil 455), average age was 57 years, 86% were commercially insured, 52% male. Gender distribution varied significantly across subgroups, lower proportion...

This study was conducted to compare adherence and persistence of patients initiating basal insulin therapy with Levemir FlexPen versus those NPH via vial syringe.Data were gathered from a large US retrospective claims database, included type 2 diabetes that initiated either or in vials. Patients defined as adherent if they had medication possession ratio (MPR) ≥80% the 12-month follow-up period persistent no gaps period.After controlling for confounders using logistic regression, 39% higher...

To describe the burden of comorbid conditions and comedications among people living with HIV (PLWH) vs. without (PLWoH).This was a case-control study conducted insured patients using administrative claims data. Adult PLWH were identified by antiretroviral therapy (ART) or HIV/AIDS diagnosis codes from 1 January 2018 to 31 December (index date set earliest claim). Continuous enrollment required for ≥12 months pre-index (baseline) ≥30 days post-index (follow-up). Patients have ≥1 during...

Objective To describe long-term (24-month) treatment patterns of patients initiating galcanezumab versus standard-of-care (SOC) preventive migraine treatments including anticonvulsants, beta-blockers, antidepressants, and onabotulinumtoxinA using administrative claims data.

Abstract Aim To describe the change in glycated haemoglobin (HbA1c) among patients with type 2 diabetes following treatment a 7 or 14 mg maintenance dose of oral semaglutide. Materials and Methods This retrospective, claims‐based study included adult pre‐index HbA1c ≥7%, initiating semaglutide between 1 November 2019 30 June 2020; had continuous health plan enrolment for ≥12 months before (pre‐index) ≥6 (post‐index) date first claim (index). Patients were required to have mg. Pre‐index...

Background: Diabetes accounts for almost 15% of all direct healthcare expenditures. Managed care organizations try to reduce costs and improve patient outcomes. Increasing persistence with antidiabetes treatment could help achieve these goals. Subjects Methods: A retrospective study was conducted using the Optum Research Database (Optum, Eden Prairie, MN) analyze clinical economic outcomes associated initiation insulin glargine via a disposable pen (GLA-P) or vial syringe (GLA-V) among...

Background Outcomes data among patients with heart failure (HF) reduced ejection fraction treated sacubitril/valsartan ( SAC / VAL ) are largely limited to clinical trial results. We compared hospitalization and healthcare costs real-world HF versus angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker ACEI ARB ). Methods Results Using retrospective administrative claims data, stable from October 2015 June 2016 were identified. Postindex assessed in propensity-matched...

Objectives For most gout patients, excruciatingly painful attacks are the major clinical burden of disease. The goal this study was to assess association frequent flares with healthcare burden, and quantify how much lower gout-related costs resource use for those infrequent compared flares. Design Retrospective cohort study. Setting Administrative claims data from a large US health plan. Participants Patients aged 18 years or above, evidence based on medical pharmacy between January 2009...

Canagliflozin is a sodium glucose co-transporter 2 inhibitor that has been shown to improve glycemic control in type diabetes mellitus (T2DM). This study aimed describe the characteristics, treatment utilization, and outcomes of patients treated with canagliflozin real world within first 6 months it being commercially available.This retrospective cohort used large US health plan database for commercial Medicare Advantage enrollees. Patients aged 18 over T2DM who filled prescription during 1...

BACKGROUND: Primary nonadherence (PNA), when a medication is newly prescribed but not filled, has been identified as major research gap potentially impacting the optimal treatment of patients with overweight and obesity who are antiobesity medications (AOMs). OBJECTIVES: To assess PNA among AOMs to examine factors associated AOMs. METHODS: This was retrospective study that used Optum Integrated Clinical plus Claims database identify individuals had at least 1 prescription order for an AOM US...

Background:Respiratory syncytial virus (RSV) lower respiratory infection (LRI) is the most common cause of hospitalization among infants <1 year age. The healthcare costs preterm with RSV LRI were compared those without in first life.Methods:This retrospective cohort study propensity-matched premature ≤36 weeks' gestational age (wGA) and/or ≤2499 g birth weight, born May 1, 2001 through April 30, 2006 (five seasons) to a national United States health plan. primary outcome was first-year and...

Type 2 diabetes mellitus (T2DM) progression often results in treatment intensification with injectable therapy to maintain glycemic control. Using pilot data from the Initiation of New Injectable Treatment Introduced after Anti-diabetic Therapy Oral-only Regimens study, real-world patterns among T2DM patients initiating insulin glargine or liraglutide were assessed. This was a retrospective analysis claims OptumInsight™ (OI; January 1, 2010 July 30, 2010) and HealthCore® (HC; June health...

Serum uric acid (sUA) levels are causally associated with the risk of gout flares. Our aim was to assess magnitude association and time first flare among patients in a managed care setting.We conducted retrospective cohort study using administrative claims data from large US health plan. Patients were required have evidence based on medical pharmacy between January 2009 April 2012. The 12 months prior index claim used baseline sUA levels; flares, stratified by levels, examined for 2 years...

Canagliflozin, an oral agent that inhibits sodium glucose co-transporter 2, improves glycemic control, body weight, and blood pressure is generally well tolerated in patients with type 2 diabetes mellitus (T2DM). This study extends the scope of previous analyses by evaluating outcomes associated use canagliflozin over a 6-month period real-world setting. retrospective cohort used data obtained from large health plan database for (≥18 years) diagnosis T2DM who filled at least one prescription...